Intervention

Aromatase Inhibitors

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 17 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17

Recruiting2

Common conditions25

Lead sponsors shown15

Clinical trials

17 shown

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerNCT07616427 · 2026-05-20

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerNCT07616453 · 2026-05-06

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNCT07596212 · 2026-09-01

NOT_YET_RECRUITING

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast CancerNCT04352777 · 2020-09-14

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)NCT04240106 · 2020-06-15

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)NCT04227327 · 2020-01-07

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerNCT04088110 · 2019-11-01

HOrmone Therapy Immediately After Histological Diagnosis of Breast CancerNCT03111615 · 2018-05-01

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionNCT03079011 · 2017-03-22

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryNCT02760030 · 2017-02-16

SFX-01 in the Treatment and Evaluation of Metastatic Breast CancerNCT02970682 · 2016-10-01

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenNCT02914158 · 2016-03-30

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsNCT02511639 · 2014-07-30

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerNCT01484041 · 2012-04-01

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast CancerNCT01298362 · 2011-03-01

Trial of Perioperative Endocrine Therapy - Individualising CareNCT02338310 · 2008-09-01

ACTIVE_NOT_RECRUITING

Overcoming Endocrine Resistance in Metastatic Breast CancerNCT02394496 · 2007-11-01

Common conditions

Leading sponsors

Second Affiliated Hospital, Zhejiang University, School of Medicine2 Centro Hospitalar Lisboa Ocidental1 Consorzio Oncotech1 Duke University1 Evgen Pharma1 First Affiliated Hospital, Sun Yat-Sen University1 Fuzhou General Hospital1 Georgetown University1 Hellenic Breast Surgeons Society1 Institute of Cancer Research, United Kingdom1 Istituto Oncologico Veneto IRCCS1 MedSIR1 Ohio State University Comprehensive Cancer Center1 UNICANCER1 University of Illinois at Chicago1

Trial status mix

COMPLETED7

UNKNOWN4

RECRUITING2

TERMINATED2

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE210

PHASE35

PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.